Nearly three years on from the start of the Covid-19 pandemic, and despite significant progress in mitigating some of its worst predictions and effects, Covid-19 remains an ongoing concern for healthcare delivery, staff health and wellbeing and patient safety.
Bringing you the latest WMAHSN news, delivered directly to your inbox, every month. In this issue, we feature news highlights, Meridian Innovation Exchange opportunities and events.
Lighting Up Tumour Treatments
The Perrier Lab have just published a new study in Angewandte Chemie which shows how polymeric nanotubes can be designed to switch their fluorescence on as they deliver a commercial anticancer drug (doxorubicin), thereby permitting the in-situ visualization of drug release. By this method, we can both treat a cancer tumour and show where the tumour is located. These theranostic systems (from therapeutic and diagnostic) form a new approach to drug delivery.
Read the paper here.
Immunotherapy combination could be alternative to ‘Extreme’ chemotherapy in some head and neck cancers
An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.
This event brings together AHSNs from across the Network and key organisation that we work with, to provide a range of insights, 1:1 confidential advice sessions, workshops and networking opportunities.